Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600436's EV-to-FCF is ranked worse than 99.12% of 565
companies
in the Drug Manufacturers industry
Industry Median: 20.96
vs SHSE:600436: 1395.58
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhangzhou Pientzehuang Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Zhangzhou Pientzehuang Pharmaceutical Co's share price for today is ¥140.02.
Zhangzhou Pientzehuang Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3.150.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Zhangzhou Pientzehuang Pharmaceutical Co EV-to-FCF Related Terms
Zhangzhou Pientzehuang Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhangzhou Pientzehuang Pharmaceutical Co EV-to-FCF Chart
Zhangzhou Pientzehuang Pharmaceutical Co Annual Data
SHSE:600436 vs LLY, JNJ, ABBV: EV-to-FCF Comparison
For the Drug Manufacturers - General subindustry, Zhangzhou Pientzehuang Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhangzhou Pientzehuang Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
Zhangzhou Pientzehuang Pharmaceutical Co's current Enterprise Value is ¥84,131 Mil.
Zhangzhou Pientzehuang Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) has a EV-to-FCF of 1,395.58 as of Jul. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhangzhou Pientzehuang Pharmaceutical Co and its competitors. This is 1774% above median its historical median of 74.47. According to the industry distribution chart, Zhangzhou Pientzehuang Pharmaceutical Co ranks #560 out of 565 companies in the Drug Manufacturers industry, placing it in the top 99.1%.
Is Zhangzhou Pientzehuang Pharmaceutical Co's EV-to-FCF too high?
Zhangzhou Pientzehuang Pharmaceutical Co's current EV-to-FCF of 1,395.58 is 1774% above median its 10-year median of 74.47. The Drug Manufacturers industry median EV-to-FCF is 20.96. Zhangzhou Pientzehuang Pharmaceutical Co's value of 1,395.58 is 6558.3% above this industry median. Based on the distribution chart, Zhangzhou Pientzehuang Pharmaceutical Co ranks #560 out of 565 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zhangzhou Pientzehuang Pharmaceutical Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhangzhou Pientzehuang Pharmaceutical Co's EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Zhangzhou Pientzehuang Pharmaceutical Co ranks #560 out of 565 companies for EV-to-FCF. This places Zhangzhou Pientzehuang Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 20.96. Zhangzhou Pientzehuang Pharmaceutical Co's value of 1,395.58 is 6558.3% above this benchmark. While the company's 10-year median is 74.47 vs. the industry median of 20.96, Zhangzhou Pientzehuang Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.96, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhangzhou Pientzehuang Pharmaceutical Co's current EV-to-FCF of 1,395.58 is 6558.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhangzhou Pientzehuang Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhangzhou Pientzehuang Pharmaceutical Co's current EV-to-FCF is 1,395.58, which is 1774% above median its own 10-year median of 74.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhangzhou Pientzehuang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥172.71, compared to a current price of ¥140.02 — trading 18.9% below its estimated fair value. The current EV-to-FCF is 1,395.58, which is 1774% above median its 10-year median of 74.47 and 6558.3% above the Drug Manufacturers industry median of 20.96. Zhangzhou Pientzehuang Pharmaceutical Co's overall GF Score™ is 86/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436), the current EV-to-FCF is 1,395.58 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) Overvalued in 2026?
Based on GuruFocus' analysis, Zhangzhou Pientzehuang Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥140.02 is trading 18.9% below its estimated GF Value™ of ¥172.71.
GuruFocus considers Zhangzhou Pientzehuang Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600436:
EV-to-FCF: 1,395.58 (1774% above median its 10-year median of 74.47)
GF Value™: ¥172.71 vs. price of ¥140.02 (18.9% below fair value)
Industry Position: 6558.3% above the Drug Manufacturers median (#560 of 565)
No single metric tells the full story. See the SHSE:600436 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhangzhou Pientzehuang Pharmaceutical Co Business Description
Zhangzhou Pientzehuang Pharmaceutical Co Ltd produces and sells Chinese medicines. The company's product categories include tablets, hard capsules, granules, pills (water pills, honey pills), syrups, tinctures (including external use), ointments, lozenges, decoctions, Chinese herbal medicine slices (including direct oral slices) (clean preparation); production of candy products (candy), health food products; and production of beverages (solid beverages).
86GF Score
Get the complete analysis for SHSE:600436
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600436 has been successfully added to your 
